1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)" is currently closed and not accepting applications.
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). This initiative supports extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in biospecimens, including blood biospecimens utilized as liquid biopsies.
Research on liquid biopsy for breast cancer brain metastasis surveillance would fit this focus.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 393 -- Cancer Cause and Prevention Research Last Updated: December 13, 2024 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO.
Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized... for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva.
Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures.
The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
For-profit organizations other than small businesses Private institutions of higher education Public and state institutions of higher education Independent school districts Special district governments Public and Indian housing authorities City or township governments Federally recognized Native American tribal governments Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated PAR-25-325-Full-Announcement.
html PAR-25-325 Full Announcement Text Dec 13, 2024 02:43 PM UTC Link to additional information https://grants. nih. gov/grants/guide/pa-files/PAR-25-325.
html Closing: September 10, 2027 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Eligible applicants include businesses (small and for-profit), educational institutions (private and public higher education, independent school districts), various government entities (state, special district, city/township, county, federally recognized Native American tribal governments, public/Indian housing authorities), and various nonprofit organizations. Confirm the full requirements in the official notice before applying.
The published deadline was December 13, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article